A prospective, single-center, randomized phase 2 trial of etoposide in severe COVID-19
Description
The systemic inflammatory response seen in patients with severe COVID-19 shares many similarities with the changes observed in hemophagocytic lymphohistiocytosis (HLH); a disease characterized by excessive immune activation. Many patients with severe
